Lack of association between CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis of 22,090 cases and 28,498 controls.
Epidemiological studies have evaluated the association between CYP17 MspA1 polymorphism and breast cancer risk. However, the results remain conflicting rather than conclusive. To derive a more precise estimation of the relationship, we performed this meta-analysis. Systematic searches of the PubMed and Medline databases were performed. A total of 35 studies including 22,090 cases and 28,498 controls were identified. Genotype distributions of CYP17 in the controls of all studies were in agreement with Hardy-Weinberg equilibrium (HWE) except for three studies. When all 35 studies were pooled into the meta-analysis, there was no evidence for significant association between CYP17 MspA1 polymorphism and breast cancer risk (for A1/A2 vs. A1/A1: OR = 1.00, 95% CI = 0.96-1.04; for A2/A2 vs. A1/A1: OR = 1.03, 95% CI = 0.97-1.08; for dominant model: OR = 1.01, 95% CI = 0.97-1.05; for recessive model: OR = 1.03, 95% CI = 0.98-1.08). In the subgroup analyses by ethnicity, menopausal status and source of controls, no significant associations were found in all genetic models. When sensitivity analyses were performed by excluding HWE-violating studies, all the results were not materially altered. In summary, the meta-analysis strongly suggests that CYP17 MspA1 polymorphism is not associated with increased breast cancer risk.
Mao
Chen
C
Department of Epidemiology, School of Public Health and Tropical Medicine, Southern Medical University, Guangzhou, China.
Wang
Xi-Wen
XW
He
Ben-Fu
BF
Qiu
Li-Xin
LX
Liao
Ru-Yan
RY
Luo
Rong-Cheng
RC
Chen
Qing
Q
D019943:Amino Acid Substitution; D001943:Breast Neoplasms / Q000453:epidemiology* / Q000208:ethnology / Q000235:genetics; D016022:Case-Control Studies; D005006:Ethnicity / Q000235:genetics / Q000706:statistics & numerical data; D005260:Female; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006801:Humans; D008593:Menopause; D008957:Models, Genetic; D016017:Odds Ratio; D018579:Patient Selection; D012150:Polymorphism, Restriction Fragment Length; D020641:Polymorphism, Single Nucleotide; D012306:Risk; D013254:Steroid 17-alpha-Hydroxylase / Q000235:genetics*
C501892:CYP17A1 protein, human; D013254:Steroid 17-alpha-Hydroxylase